RPH-002

· R-Pharm

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for RPH-002, covering 2026-02-27 to 2026-07-14. Get the full timeline:

Most recent: Clinical Trial Update: A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma [Phase 3]

See pricing